

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>CREDIT SUISSE FIRST BOSTON/</u> (Last) (First) (Middle) <u>ELEVEN MADISON AVENUE</u> (Street) <u>NEW YORK NY 10010</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>03/16/2004</u>	3. Issuer Name and Ticker or Trading Symbol <u>XCYTE THERAPIES INC [XCYT]</u>
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Convertible Promissory Note	03/19/2004 ⁽¹⁰⁾	03/19/2004	Common Stock	10,670	9.625	I	See Footnote ⁽¹⁾⁽²⁾
Series A Convertible Preferred Stock	03/19/2004 ⁽¹¹⁾	03/19/2004	Common Stock	478,466	5.225	I	See Footnote ⁽¹⁾⁽³⁾
Series B Convertible Preferred Stock	03/19/2004 ⁽¹¹⁾	03/19/2004	Common Stock	99,172	6.05	I	See Footnote ⁽¹⁾⁽⁴⁾
Series C Convertible Preferred Stock	03/19/2004 ⁽¹¹⁾	03/19/2004	Common Stock	207,805	9.185	I	See Footnote ⁽¹⁾⁽⁵⁾
Series D Convertible Preferred Stock	03/19/2004 ⁽¹¹⁾	03/19/2004	Common Stock	58,861	15.29	I	See Footnote ⁽¹⁾⁽⁶⁾
Series E Convertible Preferred Stock	03/19/2004 ⁽¹¹⁾	03/19/2004	Common Stock	64,741	15.29	I	See Footnote ⁽¹⁾⁽⁷⁾
Series F Convertible Preferred Stock	03/19/2004 ⁽¹¹⁾	03/19/2004	Common Stock	660	15.29	I	See Footnote ⁽¹⁾⁽⁸⁾
Common Stock Warrants (right to buy)	03/19/2004 ⁽¹²⁾	03/19/2004 ⁽¹³⁾	Common Stock	42,196	0.055	I	See Footnote ⁽¹⁾⁽⁹⁾

Explanation of Responses:

1. See Attachment
2. See Attachment
3. See Attachment
4. See Attachment
5. See Attachment
6. See Attachment
7. See Attachment
8. See Attachment
9. See Attachment
10. See Attachment
11. See Attachment
12. See Attachment
13. See Attachment

/s/ Ivy Dodes, on behalf of Credit Suisse First
Boston business unit 03/16/2004

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Attachment A
EXPLANATION TO RESPONSES:

Reporting Person Issuer Name and Ticker Symbol Statement for MM/DD/YY
Credit Suisse First Boston, on behalf of the Credit Suisse First Boston business unit (1)Eleven Madison AvenueNew York, New York 10010 Xcyte Therapies, Inc. (XCYT)

(1) In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Form 3 is being filed by Credit Suisse First Boston (the Bank) which owns directly a majority of the voting stock, and all of the non-voting stock, of Credit Suisse First Boston, Inc. ("CSFBI"), a Delaware corporation. The Bank is a global financial services company with two distinct business units. In addition to the CSFB business unit, CSG and its consolidated subsidiaries are comprised of the following: CSG, for purposes of the federal securities laws, may be deemed ultimately to control the Bank and the Reporting Person. CSG, its executive officers and directors,

Reporting Person Issuer Name and Ticker Symbol Statement for MM/DD/YY
Credit Suisse First Boston, on behalf of the Credit Suisse First Boston business unit (1)Eleven Madison AvenueNew York, New York 10010 Xcyte Therapies, Inc. (XCYT)

Financial Services business unit) may beneficially own shares of the securities of the issuer to which this Form relates (the "Shares") and such Shares are not reported on the issuer's financial statements. Sprout Capital VII, L.P. ("Sprout VII"), Sprout CEO Fund, L.P. ("Sprout CEO"), DLJ First ESC, L.P. ("ESC") and Sprout Plan Investors, L.P. ("Plan Investors") are Delaware limited liability partnerships. DLJ LBO Plans Management Corporation ("DLJLBO"), a Delaware corporation, is the general partner of ESC and, as such, is responsible for its day-to-day management. DLJLBO includes 213 shares of Common Stock, upon conversion of convertible promissory notes held of record by DLJ Capital Corporation, 1,066 shares of Common Stock,

Reporting Person Issuer Name and Ticker Symbol Statement for MM/DD/YY
Credit Suisse First Boston, on behalf of the Credit Suisse First Boston business unit (1)Eleven Madison AvenueNew York, New York 10010 Xcyte Therapies, Inc. (XCYT)

(3) Includes 9,569 shares of Series A Convertible Preferred Stock held of record by DLJ Capital Corporation., 47,846 shares of Series A Convertible Preferred Stock held of record by DLJ Capital Corporation., 9,917 shares of Series B Convertible Preferred Stock held of record by DLJ Capital Corporation., 9,917 shares of Series B Convertible Preferred Stock held of record by DLJ Capital Corporation., 20,780 shares of Series C Convertible Preferred Stock held of record by DLJ Capital Corporation., 5,886 shares of Series D Convertible Preferred Stock held of record by DLJ Capital Corporation., 6,540 shares of Series E Convertible Preferred Stock held of record by DLJ Capital Corporation.,

Reporting Person Issuer Name and Ticker Symbol Statement for MM/DD/YY
Credit Suisse First Boston, on behalf of the Credit Suisse First Boston business unit (1)Eleven Madison AvenueNew York, New York 10010 Xcyte Therapies, Inc. (XCYT)

(8) Includes 660 shares of Series F Convertible Preferred Stock held of record by Sprout CEO Fund, L.P. Each entity other than the entity that directly holds the shares of Series F Convertible Preferred Stock is a limited partner of Sprout CEO Fund, L.P. (8) Includes 843 shares of Common Stock issuable upon exercise of warrants held of record by DLJ Capital Corporation, 4,219 shares of Common Stock issuable upon exercise of warrants held of record by DLJ Capital Corporation. These convertible promissory notes will be converted into common stock upon the completion of the initial public offering ("IPO"). Immediately following the closing of the IPO of the Issuer's common stock, all outstanding shares of preferred stock will be converted into common stock of the Issuer. This warrant will be exercised upon the closing of the IPO through a net exercise feature at the IPO price. The warrant expires upon the closing of the IPO.